A Role of MicroRNAs in Pathogenesis of Renal Cell Carcinoma

Mytsyk, Yulian; Borys, Yuriy; Dosenko, Viktor Е.; Diychuk, Yuriy; Kowalskyy, Vasyl; Pasichnyk, S. M.; Matskevych, V. M.; ILLJUK, P.

doi:10.25040/ecpb2017.03.050

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mikami showed that the expression of Slug negatively correlates with the stage of RCC, and although some members of the Snail family are inducers of EMT, Slug did not affect this process [33]. On the contrary, Mystyk stated Slug as a prognostic factor, highlighting its role both during EMT and during cell migration [34]. In present study, we have shown that tumors with a sarcomatoid component express Slug significantly more often.…”

Section: Discussionmentioning

confidence: 38%

SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival

Zivotic,

Kovacevic,

Nikolic

et al. 2023

IJMS

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the deadliest urological neoplasm. Up to date, no validated biomarkers are included in clinical guidelines for the screening and follow up of patients suffering from RCC. Slug (Snail2) and Snail (Snail1) belong to the Snail superfamily of zinc finger transcriptional factors that take part in the epithelial–mesenchymal transition, a process important during embryogenesis but also involved in tumor progression. We examined Slug and Snail immunohistochemical expression in patients with different stages of renal cell carcinomas with the aim to investigate their potential role as staging and prognostic factors. A total of 166 samples of malignant renal cell neoplasms were analyzed using tissue microarray and immunohistochemistry. Slug and Snail expressions were evaluated qualitatively (presence or absence), in nuclear and cytoplasmic cell compartments and compared in relation to clinical parameters. The Kaplan–Meier survival analysis showed the impact of the sarcomatoid component and Slug expression on the survival longevity. Cox regression analysis separated Slug as the only independent prognostic factor (p = 0.046). The expression of Snail was associated with higher stages of the disease (p = 0.004), especially observing nuclear Snail expression (p < 0.001). All of the tumors that had metastasized showed nuclear immunoreactivity (p < 0.001). In clear cell RCC, we showed a significant relationship between a high nuclear grade and nuclear Snail expression (p = 0.039). Our results suggest that Slug and Snail could be useful immunohistochemical markers for staging and prognosis in patients suffering from various RCCs, representing potential targets for further therapy strategies of renal cancer.

show abstract

Section: Discussionmentioning

confidence: 38%

SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival

Zivotic,

Kovacevic,

Nikolic

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The methylation of FOXP3 is a marker of regulatory T cells. The regulatory T cell population was significantly expanded in non-responders to immunotherapy as compared to therapy-responding patients [111] miR-183 miR-183 predicts the response of renal cancer cells to NK cell therapy Primary renal cancer cells with under-expressed miR-183 were more responsive to NK cell therapy [112] miR-484/miR-155-5p Patients with significantly up-regulated levels of miR-484/miR-155-5p are refractory to sunitinib treatment [113] miR-942 miR-942 was observed to be overexpressed in sunitinib resistant cell line Caki-2 and hence is a predictor of sunitinib efficacy [114] miR-22; miR-24; miR-99a; miR-194; miR-214; miR-335; miR-339; miR-708 These miRNA were specifically induced in long responders to nivolumab but were silenced to baseline in patients with metastatic ccRCC [49] miR-133a; miR-628-5p…”

Section: Foxp3mentioning

confidence: 99%

Biomarkers in renal cell carcinoma and their targeted therapies: a review

Gupta,

Shamsher Singh

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most life-threatening urinary malignancies displaying poor response to radiotherapy and chemotherapy. Although in the recent past there have been tremendous advancements in using targeted therapies for RCC, despite that it remains the most lethal urogenital cancer with a 5-year survival rate of roughly 76%. Timely diagnosis is still the key to prevent the progression of RCC into metastatic stages as well as to treat it. But due to the lack of definitive and specific diagnostic biomarkers for RCC and its asymptomatic nature in its early stages, it becomes very difficult to diagnose it. Reliable and distinct molecular markers can not only refine the diagnosis but also classifies the tumors into thier sub-types which can escort subsequent management and possible treatment for patients. Potential biomarkers can permit a greater degree of stratification of patients affected by RCC and help tailor novel targeted therapies. The review summarizes the most promising epigenetic [DNA methylation, microRNA (miRNA; miR), and long noncoding RNA (lncRNA)] and protein biomarkers that have been known to be specifically involved in diagnosis, cancer progression, and metastasis of RCC, thereby highlighting their utilization as non-invasive molecular markers in RCC. Also, the rationale and development of novel molecular targeted drugs and immunotherapy drugs [such as tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs)] as potential RCC therapeutics along with the proposed implication of these biomarkers in predicting response to targeted therapies will be discussed.

show abstract

“…miRNAs belong to the class of non-coding endogenous RNA, also characterized as small single-stranded nucleotides which play a key regulatory role in various biological processes in plants and animals (28,29). miRNAs range from 21 to 25 nucleotides in length and work by targeting the specific mRNA by translational inhibition, degradation, or mRNA destabilization to regulate the target (29,30).…”

Section: Understanding the Mirnasmentioning

confidence: 99%

miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review)

et al. 2022

View full text Add to dashboard Cite

Cancer is recognized as the leading cause of death worldwide. The hippo signaling pathway regulates organ size by balancing cell proliferation and cell death; hence dysregulation of the hippo pathway promotes cancer-like conditions. miRNAs are a type of non-coding RNA that have been shown to regulate gene expression. miRNA levels are altered in various classes of cancer. Researchers have also uncovered a crosslinking between miRNAs and the hippo pathway, which has been linked to cancer. The components of the hippo pathway regulate miRNA synthesis, and various miRNAs regulate the components of the hippo pathway both positively and negatively, which can lead to cancer-like conditions. In the present review article, the mechanism behind the hippo signaling pathway and miRNAs biogenesis and crosslinks between miRNAs and the hippo pathway, which result in cancer, shall be discussed. Furthermore, the article will cover miRNA-related therapeutics and provide an overview of the development of resistance to anticancer drugs. Understanding the underlying processes would improve the chances of developing effective cancer treatment therapies.

show abstract

A Role of MicroRNAs in Pathogenesis of Renal Cell Carcinoma

Cited by 3 publications

References 17 publications

SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival

SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival

Biomarkers in renal cell carcinoma and their targeted therapies: a review

miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review)

Contact Info

Product

Resources

About